[The use of Ergocomb in symptoms of cerebrovascular insufficiency].
Using a test design of subjective, clinical and psychometric parameters, Ergocomb was tested, in a double-blind trial, on fifty-five patients with cerebrovascular insufficiency. The test results, which are in agreement with those reported in the literature, show a substantial improvement of various subjective and objective criteria. Therefore, Ergocomb, in the form of swallowable tablets, is considered suitable for application to patients with senile cerebral insufficiency, the recommended dosage being 3 x 1 mg.
D000368:Aged; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000523:psychology; D004088:Dihydroergotoxine / Q000627:therapeutic use*; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008606:Mental Processes / Q000187:drug effects; D011581:Psychological Tests
D004088:Dihydroergotoxine
Zum Einsatz von Ergocomb bei Symptomen der zerebrovaskulären Insuffizienz.